AstraZeneca PLC (AZN) Net Profit Margin: 17.19%
Is AstraZeneca PLC’s net profit margin high or low?
AstraZeneca PLC's net profit margin of 17.19% is 63% above its 5-year average of 10.53%, near the high end of its 5-year range (0.30%–17.46%).
As of Friday, June 12, 2026. 12.83% above its 12-month average of 15.23%.
AZN Net Profit Margin Chart
AZN Average Net Profit Margin Chart
AZN Current vs Average Net Profit Margin Chart
AZN Net Profit Margin Metrics
NET PROFIT MARGIN
17.19%
NET PROFIT MARGIN AVG TTM
15.23%
NET PROFIT MARGIN AVG 3Y
12.72%
NET PROFIT MARGIN AVG 5Y
10.53%
NET PROFIT MARGIN AVG 10Y
10.77%
NET PROFIT MARGIN AVG 15Y
13.06%
NET PROFIT MARGIN AVG 20Y
14.89%
CURRENT VS TTM AVG
+12.83%
CURRENT VS 3Y AVG
+35.14%
CURRENT VS 5Y AVG
+63.22%
CURRENT VS 10Y AVG
+59.68%
CURRENT VS 15Y AVG
+31.60%
CURRENT VS 20Y AVG
+15.46%
AZN Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 17.19% | 15.23% | 12.72% | 10.53% |
| Merck & Co., Inc. (MRK) | $298.29B | 13.62% | 27.40% | 19.98% | 20.62% |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 2.68% | 3.15% | 4.63% | 5.09% |
| Amgen Inc. (AMGN) | $191.09B | 20.95% | 16.61% | 20.49% | 22.20% |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 15.18% | 14.95% | 14.84% | 16.47% |
| AbbVie Inc. (ABBV) | $397.12B | 5.79% | 7.25% | 10.96% | 12.41% |
| Gilead Sciences, Inc. (GILD) | $156.28B | 30.99% | 15.29% | 17.07% | 15.27% |
| Abbott Laboratories (ABT) | $156.15B | 13.91% | 23.34% | 19.20% | 17.71% |
| Pfizer Inc. (PFE) | $149.18B | 11.83% | 12.51% | 14.97% | 18.18% |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 28.15% | 28.09% | 25.67% | 26.14% |
Margin Comparison
Operating Margin
23.7%
Net Profit Margin
17.2%
AstraZeneca PLC Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Net Profit Margin FAQ
- What is the net profit margin for AstraZeneca PLC (AZN)?
- The net profit margin for AZN stock is 17.19%.
- Is AstraZeneca PLC's net profit margin high or low?
- AstraZeneca PLC's net profit margin of 17.19% is 63% above its 5-year average of 10.53%, near the high end of its 5-year range (0.30%–17.46%).
- What is the TTM average net profit margin for AstraZeneca PLC (AZN)?
- The TTM average net profit margin for AZN stock is 15.23%.
- What is the 3Y average net profit margin for AstraZeneca PLC (AZN)?
- The 3Y average net profit margin for AZN stock is 12.72%.
- What is the 5Y average net profit margin for AstraZeneca PLC (AZN)?
- The 5Y average net profit margin for AZN stock is 10.53%.
- What is the 10Y average net profit margin for AstraZeneca PLC (AZN)?
- The 10Y average net profit margin for AZN stock is 10.77%.
- What is the 15Y average net profit margin for AstraZeneca PLC (AZN)?
- The 15Y average net profit margin for AZN stock is 13.06%.
- What is the 20Y average net profit margin for AstraZeneca PLC (AZN)?
- The 20Y average net profit margin for AZN stock is 14.89%.
AstraZeneca PLC Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 17.46% |
| 2024-12-31 | 13.01% |
| 2023-12-31 | 13.00% |
| 2022-12-31 | 7.41% |
| 2021-12-31 | 0.30% |
| 2020-12-31 | 12.01% |
| 2019-12-31 | 5.47% |
| 2018-12-31 | 9.76% |
| 2017-12-31 | 13.36% |
| 2016-12-31 | 15.21% |
| 2015-12-31 | 11.43% |
| 2014-12-31 | 4.64% |
| 2013-12-31 | 9.90% |
| 2012-12-31 | 22.31% |
| 2011-12-31 | 29.52% |
| 2010-12-31 | 24.21% |
| 2009-12-31 | 22.93% |
| 2008-12-31 | 19.31% |
| 2007-12-31 | 18.93% |
| 2006-12-31 | 22.83% |
| 2005-12-31 | 19.65% |
| 2004-12-31 | 17.10% |
| 2003-12-31 | 16.11% |
| 2002-12-31 | 15.90% |
| 2001-12-31 | 25.22% |
| 2000-12-31 | 14.02% |
| 1999-12-31 | 7.55% |
| 1998-12-31 | 10.47% |
| 1997-12-31 | 14.05% |
| 1996-12-31 | 11.99% |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot